Similar results were observed in PP-MS during the OLE phase of the ORATORIO trial, with persistent suppression of MRI inflammatory activity in patients receiving continuous ocrelizumab, and almost complete and sustained suppression of new MRI lesion disease activity throughout the OLE in those switching from IFN to ocrelizumab. This evidence concerns the gene IFNA1 and myeloid sarcoma.